Young, bright and committed to labtech

Ghazal Voghoui recently bought her first apartment and finally settled in Stockholm again. Last year, she finished her law studies and she is relieved to be back after living in Geneva for four years. On November 10 she will take a big career leap, becoming the new CEO of Swedish Labtech.

Cate Poulsen, Qiagen

Why are you going to Scanlab and Biotech Forum?

Dry blood DNA storage on a matrix

Qiagen recently presented a method of dry blood sample storage as an alternative to storage in freezers.

Diagnostics to deal with new diseases

Maria Brytting at the Swedish Institute for Infectious Disease Control, SMI, will share her experiences from April 2009 when the new influenza A virus, H1N1, was first reported globally.

Reidar Rasmussen, Labmodul

Why are you going to Scanlab and Biotech Forum?

Age essential when testing drugs

Anders Rane has been arguing that genes and age are both important factors in understanding how medicines affect individuals. Only last year, the EU established regulations stating that pharmaceuticals must be tested for children as well as for adults.

Annika Garnås, LAB

Why are you going to Scanlab+Biotech Forum?

How to get the most out of the fair

Life science in Stockholm

Sweden has the fourth-largest biotech market in Europe. More than half of its biotechnology enterprise, some 460 companies, is located in the Stockholm region.

EU-larmet om antibiotikaläget överdrivet

Enligt EU finns det bara 15 läkemedelskandidater i världen som kan bli avgörande för bekämpningen av multiresistenta bakterier. Siffran orsakade ett larm när rapporten presenterades i mitten av september. Men undersökningen tar bara hänsyn till substanser i klinisk fas.

Nya utmaningar för vaccinbolag

Sedan 2006 har den globala kapaciteten för att tillverka influensavaccin ökat från 400 miljoner doser per år till 900 miljoner. -Det här är ingen business as usual för vaccinbolagen, säger Albert Osterhaus, chef för institutionen för virologi på Rotterdams universitet.

Klartecken för Innates namnbyte

Bolagsverket har godkänt Umeåföretagets nya namn Creative Antibiotics.

The winner of the race

She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.

With their hands on the legal levers

It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.

Innate Pharmaceuticals byter namn

Creative Antibiotics vill bolaget istället heta.

Biologer blir hedersdoktorer

Till vardags har de tre världsledande forskarna sin hemmabas i Tokyo, San Diego och vid Sahlgrenska Instutet. I maj blir blir de promoverade till hedersdoktorer vid Chalmers Tekniska Högskola.

Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Swedish top scientists to EMBO

Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.

Faster sales but less profits for Probi

The probiotic company increases its turnover, and the net results are twice as large as last year.

Re-painting the big pig-ture

Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.

Athera signs production partnership

The companys novel cardiovascular product will be manufactured in Germany.

Test if you carry the fat virus

In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.

Teams up with leading dermatologist

Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.